December 7, 2021 9:00 am +00:00

MSD appoints Alloga and Alliance Healthcare as its exclusive distribution partners

Alloga (warehousing and logistics) and Alliance Healthcare (wholesaler) will manage the MSD in the UK portfolio from early 2022.

LONDON, December 7, 2021 – MSD (tradename Merck & Co., Inc., Kenilworth, N.J., USA (NYSE: MRK)) announced today that it has appointed Alloga and Alliance Healthcare Ltd. as its exclusive wholesaler distribution partner in the UK.

From early 2022, Alloga will exclusively manage the warehousing and logistics and Alliance Healthcare Limited will be the wholesaler for MSD products across the UK ensuring MSD vaccines and medicines get to those who need them.

The new distribution partnership with Alliance Healthcare is the result of a competitive and thorough tender process which was conducted to enable MSD to continually meets the needs of patients and those who care for them by ensuring timely distribution of products to hospitals, pharmacies, GP surgeries and clinics. The new partnership includes a strong network of dispensing points across the UK – all of which will optimise support for patients and ensure that those who need MSD’s vaccines and medicines can receive them.

David Peacock, Managing Director of MSD in the UK, said: “At MSD our mission is to save and improve lives, for us to do this we need to implement and maintain timely and efficient distribution of the many products and vaccines which make up our portfolio.

“Following a thorough and competitive process we believe that both Alloga and Alliance Healthcare will be strong partners in helping us to achieve this by delivering a robust, transparent and efficient supply chain and we look forward to working with them.”

Owen Cooper, Client Services Director, Alliance Healthcare, said: “We are truly delighted to be working with MSD again and to be their sole distributor to all customers in the UK and Northern Ireland.  Partnership and patient focus are the foundation of everything we do here at Alliance Healthcare, so being able to build upon this strong relationship with MSD to provide an efficient and flexible ‘pallet to patient’ supply chain will deliver value and benefit for all.”   

Chris Williams, Managing Director, Alloga, continued: “We are incredibly proud of how our business has responded throughout the recent challenging years, our motivated teams adapted to these changes to enable the very best patient outcomes.   That this has been recognised by MSD is one of our greatest achievements of 2021 and we are honoured to be working with them going forward.”

About MSD

For more than 130 years, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives.  MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs, and partnerships. Today, MSD continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit www.msd-uk.com and connect with us @MSDintheUK on Twitter, Instagram, LinkedIn, YouTube and Facebook.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether because of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2019 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

GB-NON-04806 | Date of Preparation: December 2021